Živković Samardžić advised Manchester-based biotech firm APIS Assay Technologies Ltd., specializing in biomarker-based diagnostic assays with integrated AI, on the Serbian aspects of its acquisition of BeoGenomics, a software developer with expertise in bioinformatics and artificial intelligence (BIOX).

BeoGenomics develops on-premise and secure cloud-based data analysis solutions, helping clients build customized genomics and proteomics pipelines. The start-up will be integrated into APIS to support the launch of a new BIOX service line, complementing APIS’s biomarker R&D efforts.

APIS focuses on developing diagnostic tests for disease prediction, prevention, and diagnosis, with a business model centered on three areas: biomarker diagnostics, molecular diagnostic contract development, and applied bioinformatics.

Živković Samardžić’s role included due diligence of BeoGenomics, drafting and negotiating transactional documents, structuring the deal, and providing comprehensive legal advice on post-closing activities.